April 14, 2020 Forthcoming
Reference - 432 Pages - 173 Color Illustrations
ISBN 9780367279400 - CAT# K426100
SAVE ~$31.00 on each
The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death?
The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many "access journey" obstacles that typify today’s much changed pharmaceutical environment.
This 3rd edition is significantly expanded with 10 new chapters and revised and updated throughout to reflect today’s environment. Contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global player environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.
List of Figures, List of Tables, List of Abbreviations, Foreword by Andrea Mantovani, Acknowledgements, Preface, About the Author, Introduction, Part A The Challenges of Drug Pricing and Market Access, 1 Why is drug pricing different? 2 The Age of Value and Affordability, 3 The Access Journey, 4 Fair Pricing, Part B Traveling the Access Journey, 5 Payers, 6 Medical Community, 7 Provider Organizations, 8 Patients, Part C Pricing and Payer Management Techniques, 9 Fundamentals of Pricing, 10 Reference-Based Pricing, 11 Health Economics and Outcomes Research, 12 Attributes, Benefits, Value and Price, Part D Structured Access and Pricing Approaches, 13 Pricing and Drug Development, 14 Payer Segmentation, 15 The PODiUM Framework, 16 BEST Framework, 17 Development Options and Decisions, 18 Value Story and Messaging, Part E Developing an Integrated Global Strategy, 19 Developing a Global Pricing Strategy, 20 Public Policy, 21 Oncology and Orphan Drugs, 22 Gene Therapy Pricing and Funding, 23 Biosimilars, 24 Payer and Pricing Research, Part F Access and Pricing Strategy Implementation, 25 Organizing for Access, 26 Access and Price Negotiations, 27 Value-based Agreements, 28 Creating Win-Win Deals, Part G Key Health Care Systems, 29 United States, 30 Canada, 31 France, 32 Germany, 33 Italy, 34 Spain, 35 United Kingdom, 36 Japan, 37 Australia, 38 Brazil, 39 China, 40 India, 41 South Korea, References, Index